Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ: REGN )

1,012.82 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 526
Open 1,012.82
Bid (Size) 1,012.00 (1)
Ask (Size) 1,023.00 (1)
Prev. Close 1,012.82
Today's Range 1,012.82 - 1,012.82
52wk Range 769.19 - 1,211.20
Shares Outstanding 91,779,465
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Should You Buy the Dip on This Top Growth Stock?
The biotech needs to overcome an issue most drugmakers face at some point. 
Via The Motley Fool
A Closer Look at 24 Analyst Recommendations For Regeneron Pharmaceuticals
Via Benzinga

Performance

YTD
+11.91%
+11.91%
1 Month
-10.49%
-10.49%
3 Month
-3.75%
-3.75%
6 Month
+7.92%
+7.92%
1 Year
+21.76%
+21.76%

More News

Read More
Market Whales and Their Recent Bets on REGN Options
Via Benzinga
(REGN) - Analyzing Regeneron Pharmaceuticals's Short Interest
Via Benzinga
$100 Invested In This Stock 5 Years Ago Would Be Worth $400 Today
Via Benzinga
Regeneron Pharma, Super Micro Computer And Global Payments Are Among Top 10 Large Cap Losers Last Week (Sept 23-Sept 27): Are The Others In Your Portfolio?
Via Benzinga
A Closer Look at Regeneron Pharmaceuticals's Options Market Dynamics
Via Benzinga
Exploring The Competitive Space: Regeneron Pharmaceuticals Versus Industry Peers In Biotechnology
Via Benzinga
Smart Money Is Betting Big In REGN Options
Via Benzinga
Stock Market Rally Hits Fresh Highs, Fueled By Micron Earnings, China Stimulus: Weekly Review
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
FDA Approves Regeneron/Sanofi's Blockbuster Dupixent For Smoker's Lung Disease
Via Benzinga
Exposures Product Safety
Regeneron And Sanofi Snag Their $6 Billion-Potential COPD Approval For Dupixent
Via Investor's Business Daily
Exposures Product Safety
Dupixent® (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients with COPD
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Dupixent® (dupilumab) Approved in China as the First-ever Biologic Medicine for Patients with Chronic Obstructive Pulmonary Disease (COPD)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Regeneron to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on October 31, 2024
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Taiwan Semiconductor, American Tower, Trane Technologies And A Health Care Stock On CNBC's 'Final Trades'
Via Benzinga
Amgen's Rocatinlimab Data Beats Placebo In Atopic Dermatitis Trial, But Analyst Says Data Raises Concerns Amid Competitive Market
Via Benzinga
Why Is Regeneron Pharmaceuticals Stock Trading Lower On Tuesday?
Via Benzinga
This BP Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
Via Benzinga
Tesla Leads S&P 500 Index, While Biotech Giant Tumbles On Court Ruling
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Regeneron Dives As Amgen Tees Up Its Rival To Moneymaking Machine Eylea
Via Investor's Business Daily
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Eosinophilic Esophagitis (EoE) in Children as Young as 1 Year Old
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Dupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Time To Invest And Or Trade In Bio-Tech Stocks?
Via Talk Markets
Topics ETFs
Biotech Breakout: Stocks for Your Watchlist
Via MarketBeat
Topics ETFs
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.